Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $288.67 million. The enterprise value is $238.07 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, after market close.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 227.30 million shares outstanding. The number of shares has increased by 22.21% in one year.
| Current Share Class | 227.30M |
| Shares Outstanding | 227.30M |
| Shares Change (YoY) | +22.21% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 3.13% |
| Owned by Institutions (%) | 58.88% |
| Float | 183.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.35 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 32.28 |
| P/OCF Ratio | 32.19 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 26.21 |
Financial Position
The company has a current ratio of 5.71
| Current Ratio | 5.71 |
| Quick Ratio | 5.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 22.32 |
| Interest Coverage | -4.92 |
Financial Efficiency
Return on equity (ROE) is -500.57% and return on invested capital (ROIC) is -15.84%.
| Return on Equity (ROE) | -500.57% |
| Return on Assets (ROA) | -12.68% |
| Return on Invested Capital (ROIC) | -15.84% |
| Return on Capital Employed (ROCE) | -23.57% |
| Revenue Per Employee | $859,241 |
| Profits Per Employee | -$353,366 |
| Employee Count | 145 |
| Asset Turnover | 0.46 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Gossamer Bio has paid $893,000 in taxes.
| Income Tax | 893,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +148.82% in the last 52 weeks. The beta is 1.85, so Gossamer Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.85 |
| 52-Week Price Change | +148.82% |
| 50-Day Moving Average | 1.05 |
| 200-Day Moving Average | 1.00 |
| Relative Strength Index (RSI) | 58.64 |
| Average Volume (20 Days) | 1,520,466 |
Short Selling Information
The latest short interest is 11.08 million, so 4.88% of the outstanding shares have been sold short.
| Short Interest | 11.08M |
| Short Previous Month | 10.54M |
| Short % of Shares Out | 4.88% |
| Short % of Float | 6.03% |
| Short Ratio (days to cover) | 6.71 |
Income Statement
In the last 12 months, Gossamer Bio had revenue of $124.59 million and -$51.24 million in losses. Loss per share was -$0.23.
| Revenue | 124.59M |
| Gross Profit | 124.59M |
| Operating Income | -54.77M |
| Pretax Income | -172.58M |
| Net Income | -51.24M |
| EBITDA | -54.19M |
| EBIT | -54.77M |
| Loss Per Share | -$0.23 |
Full Income StatementBalance Sheet
The company has $257.93 million in cash and $202.79 million in debt, giving a net cash position of $55.15 million or $0.24 per share.
| Cash & Cash Equivalents | 257.93M |
| Total Debt | 202.79M |
| Net Cash | 55.15M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | -6.25M |
| Book Value Per Share | -0.03 |
| Working Capital | 227.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $9.11 million and capital expenditures -$26,000, giving a free cash flow of $9.08 million.
| Operating Cash Flow | 9.11M |
| Capital Expenditures | -26,000 |
| Free Cash Flow | 9.08M |
| FCF Per Share | $0.04 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -43.96% and -41.13%.
| Gross Margin | 100.00% |
| Operating Margin | -43.96% |
| Pretax Margin | -40.41% |
| Profit Margin | -41.13% |
| EBITDA Margin | -43.49% |
| EBIT Margin | -43.96% |
| FCF Margin | 7.29% |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.21% |
| Shareholder Yield | -22.21% |
| Earnings Yield | -17.47% |
| FCF Yield | 3.10% |
Analyst Forecast
The average price target for Gossamer Bio is $7.75, which is 510.24% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.75 |
| Price Target Difference | 510.24% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 25.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gossamer Bio has an Altman Z-Score of -5.3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.3 |
| Piotroski F-Score | 2 |